Lower rates and potential deregulation could further fuel biotech M&A as we head into 2025. "The election results could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback